Small molecule JAK inhibitors for the treatment of atopic dermatitis and the patent research
This article compares the approved and under-developing small molecule JAK inhibitors for the treatment of atopic dermatitis(AD)in the world,and analyzes the R&D progress of the five key drugs ruxolitinib,baricitinib,upadacitinib,delgocitinib and abrocitinib,as well as their disclosed patents on various technical topics such as compounds and new uses.It is expected to provide effective product information and patent information for biomedical enterprises in their projects and development of small molecule JAK inhibitors for the treatment of atopic dermatitis,as well as in their new patent mining,patent protection and patent layout.
atopic dermatitisJanus kinase inhibitorruxolitinibbaricitinibupadacitinibdelgocitinibabrocitinibpatent research
NETL
NSTL
万方数据
